The Federal Prisons Naloxone Access Act requires the Bureau of Prisons to stock naloxone (an opioid-reversing medication) at all federal correctional facilities and make it accessible to both staff and incarcerated people in common areas including medical units, housing areas, dining halls, and recreation spaces. The bill mandates that facility personnel and incarcerated individuals receive annual training from medical staff on how to recognize and respond to opioid overdoses, with the medication properly maintained at room temperature and regularly checked for expiration. The law protects incarcerated people from legal liability when they administer naloxone in good faith to help someone experiencing an overdose, and requires detailed record-keeping whenever the medication is used. The Bureau of Prisons must submit annual reports to Congress documenting compliance, overdose incidents, and training completion at each facility. The legislation authorizes $6 million in funding for fiscal year 2026 to cover training, medication purchase, and initial reporting, followed by $2 million annually for fiscal years 2027 and 2028 to maintain supplies and continue the program.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.